(CMPS) Compass Pathways - Overview

Exchange: NASDAQ • Country: United Kingdom • Currency: USD • Type: Common Stock • ISIN: US20451W1018

Stock: Psilocybin, Therapy, Depression, Trials

Total Rating 40

Risk 81

Buy Signal 0.16

Medical Care Facilities » Health Care Services
Age: 5.4y

Market Cap: 642m
Avg Trading Vol: 9.46M USD

ATR: 7.83%
Peers RS (IBD): 81.08

EPS (Earnings per Share)

EPS CAGR: 24.73%
EPS Trend: 37.7%

Last SUE: 0.11
Qual. Beats: 0

Revenue

Rev. CAGR: 0.00%
Rev. Trend: 2.8%

Last SUE: 0.00
Qual. Beats: 0

Risk 5d forecast
Volatility	87.5%
Relative Tail Risk	-11.5%

Reward TTM
Sharpe Ratio	0.80
Alpha	8.29

Character TTM
Beta	1.010
Beta Downside	1.486

Drawdowns 3y
Max DD	81.00%
CAGR/Max DD	-0.16

Description: CMPS Compass Pathways December 30, 2025

Compass Pathways plc (NASDAQ:CMPS) is a UK-based biotech focused on developing psychedelic-based therapies for mental-health disorders. Its lead candidate, COMP360, is a synthetic psilocybin formulation currently in a Phase III trial for treatment-resistant depression and in Phase II trials for post-traumatic stress disorder and anorexia nervosa.

As of the latest filing, Compass holds approximately $150 million in cash and equivalents, giving it a runway of roughly 18 months at current burn rates. The company’s market capitalization hovers near $500 million, and it is positioned to benefit from the expanding global mental-health market, which is projected to grow at a 5-6% CAGR through 2030. Regulatory momentum is also notable: the FDA has granted Breakthrough Therapy Designation for COMP360, and the upcoming European Medicines Agency (EMA) review could further de-risk the pathway to commercialization.

For a deeper, data-driven assessment of CMPS’s valuation and risk profile, you may find the analytical tools on ValueRay worth exploring.

Piotroski VR‑10 (Strict, 0-10) 0.5

Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM)
FCF/TA: -0.63 > 0.02 and ΔFCF/TA -20.53 > 1.0
NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev)
CFO/TA -0.63 > 3% & CFO -161.2m > Net Income -237.3m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 1.23 > 1.5 & < 3
Outstanding Shares: last quarter (95.3m) vs 12m ago 39.39% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 0.0% > 50% (prev 1.49%; Δ -1.49% > 0%)
Interest Coverage Ratio: -51.39 > 6 (EBITDA TTM -231.3m / Interest Expense TTM 4.51m)

Altman Z'' -15.00

A: 0.18 (Total Current Assets 242.4m - Total Current Liabilities 197.4m) / Total Assets 255.6m
B: -2.85 (Retained Earnings -728.7m / Total Assets 255.6m)
C: -0.92 (EBIT TTM -231.5m / Avg Total Assets 251.5m)
D: -3.41 (Book Value of Equity -742.9m / Total Liabilities 218.0m)
Altman-Z'' Score: -17.91 = D

What is the price of CMPS shares?

As of February 07, 2026, the stock is trading at USD 6.19 with a total of 1,128,278 shares traded.
Over the past week, the price has changed by -7.47%, over one month by -12.20%, over three months by +10.73% and over the past year by +33.69%.

Is CMPS a buy, sell or hold?

Compass Pathways has received a consensus analysts rating of 4.64. Therefore, it is recommended to buy CMPS.

StrongBuy: 7
Buy: 4
Hold: 0
Sell: 0
StrongSell: 0

What are the forecasts/targets for the CMPS price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	17.3	179%
Analysts Target Price	17.3	179%
ValueRay Target Price	6.4	3.1%

CMPS Fundamental Data Overview February 03, 2026

P/B = 17.088
Revenue TTM = 0.0 USD
EBIT TTM = -231.5m USD
EBITDA TTM = -231.3m USD
Long Term Debt = 18.6m USD (from longTermDebt, last quarter)
Short Term Debt = 14.6m USD (from shortTermDebt, last quarter)
Debt = 35.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -150.8m USD (from netDebt column, last quarter)
Enterprise Value = 491.6m USD (642.4m + Debt 35.2m - CCE 185.9m)
Interest Coverage Ratio = -51.39 (Ebit TTM -231.5m / Interest Expense TTM 4.51m)
EV/FCF = -3.05x (Enterprise Value 491.6m / FCF TTM -161.2m)
FCF Yield = -32.79% (FCF TTM -161.2m / Enterprise Value 491.6m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 174.8k) / Revenue TTM)
Tobins Q-Ratio = 1.92 (Enterprise Value 491.6m / Total Assets 255.6m)
Interest Expense / Debt = 3.12% (Interest Expense 1.10m / Debt 35.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = -182.9m (EBIT -231.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.23 (Total Current Assets 242.4m / Total Current Liabilities 197.4m)
Debt / Equity = 0.94 (Debt 35.2m / totalStockholderEquity, last quarter 37.6m)
Debt / EBITDA = 0.65 (negative EBITDA) (Net Debt -150.8m / EBITDA -231.3m)
Debt / FCF = 0.94 (negative FCF - burning cash) (Net Debt -150.8m / FCF TTM -161.2m)
Total Stockholder Equity = 137.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -94.37% (Net Income -237.3m / Total Assets 255.6m)
RoE = -172.5% (Net Income TTM -237.3m / Total Stockholder Equity 137.6m)
RoCE = -148.2% (out of range, set to none) (EBIT -231.5m / Capital Employed (Equity 137.6m + L.T.Debt 18.6m))
RoIC = -108.7% (out of range, set to none) (NOPAT -182.9m / Invested Capital 168.3m)
WACC = 9.27% (E(642.4m)/V(677.5m) * Re(9.64%) + D(35.2m)/V(677.5m) * Rd(3.12%) * (1-Tc(0.21)))
Discount Rate = 9.64% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 24.04%
Fair Price DCF = unknown (Cash Flow -161.2m)
EPS Correlation: 37.73 | EPS CAGR: 24.73% | SUE: 0.11 | # QB: 0
Revenue Correlation: 2.80 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.31 | Chg30d=N/A | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=-1.18 | Chg30d=-0.017 | Revisions Net=-1 | Growth EPS=+51.5% | Growth Revenue=+0.0%

Additional Sources for CMPS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Fund Manager Positions: Dataroma | Stockcircle